EventSuperNova & NeuroNovaStem Cell Platforms for Enhanced Oncolytic VirotherapyFestival of BiologicsApril 16, 2024 Posterlaunch
EventSuperNova & NeuroNovaDeciphering Anticancer Mechanisms of Oncolytic Virus-loaded Stem CellsAmerican Association for Cancer ResearchApril 9, 2024 Posterlaunch
PublicationNeuroNovaNeural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trialLancet OncologyAugust 22, 2021 Learn Morelaunch
PublicationNeuroNovaRationale for the clinical use of adipose-derived mesenchymal stem cells for COVID-19 patientsThe Journal of Translational MedicineMay 18, 2020 Learn Morelaunch
publicationsNeuroNovaASCO-SITC Clinical Immuno-Oncology Symposium February 6-8, 2020 Orlando, Florida.Abstract 21: A cell-based platform to potentiate oncolytic virus therapiesFebruary 6, 2020 AbstractlaunchPosterlaunch
PublicationNeuroNovaFirst-in-human study of TK-positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cellsThe Journal of Translational MedicineAugust 19, 2019 Learn Morelaunch
publicationsNeuroNova33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer | November 7-11, 2018 Washington, D.C.November 7, 2018 Abstractlaunch
EventNeuroNovaThe Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.Abstract P617: A cell-based platform to protect and enhance oncolytic virus therapiesNovember 7, 2018 AbstractlaunchPosterlaunch
EventNeuroNovaThe Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting | November 7-11, 2018 Washington, D.C.Abstract P609: First in man study of TK positive oncolytic vaccinia virus delivered by adipose stromal vascular fraction cellsNovember 7, 2018 AbstractlaunchPosterlaunch
